Download PDF
Semin Liver Dis 2015; 35(02): 146-156
DOI: 10.1055/s-0035-1550054
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Liver Fibrosis in Alcoholic Liver Disease

Ramon Bataller
1   Division Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, North Carolina
,
Bin Gao
2   Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland
› Author Affiliations
Further Information

Publication History

Publication Date:
14 May 2015 (online)

    Permissions and Reprints

Abstract

Excessive alcohol consumption causes a wide spectrum of liver disease, ranging from simple steatosis to severe forms of liver injury such as steatohepatitis, liver fibrosis, cirrhosis, and liver cancer. Moreover, alcohol consumption also accelerates liver fibrosis in patients with other types of liver diseases such as viral hepatitis and nonalcoholic fatty liver disease. Virtually all clinical complications of alcoholic liver disease occur in patients with established fibrosis and cirrhosis, thus making fibrosis a key parameter for treatment and prognosis of patients. Here, the authors review diagnosis, management, and antifibrotic therapy of alcoholic liver fibrosis. They discuss both the unique features of alcoholic liver fibrosis and the similarities to liver fibrosis from other etiologies, and review molecular pathogenesis and animal models. Finally, future directions for basic and clinical research on alcoholic liver fibrosis are proposed.

Keywords

alcoholic hepatitis - hepatic stellate cells - steatohepatitis - animal models
 

  • References

  • 1 Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360 (26) 2758-2769
    CrossrefPubMedGoogle Scholar
  • 2 Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141 (5) 1572-1585
    CrossrefPubMedGoogle Scholar
  • 3 Ueno A, Lazaro R, Wang PY, Higashiyama R, Machida K, Tsukamoto H. Mouse intragastric infusion (iG) model. Nat Protoc 2012; 7 (4) 771-781
    CrossrefPubMedGoogle Scholar
  • 4 Bertola A, Mathews S, Ki SH, Wang H, Gao B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc 2013; 8 (3) 627-637
    CrossrefPubMedGoogle Scholar
  • 5 Chen CM, Yoon YH, Yi HY, Lucas DL. Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis. Alcohol Clin Exp Res 2007; 31 (2) 285-292
    CrossrefPubMedGoogle Scholar
  • 6 Roulot D, Costes JL, Buyck JF , et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011; 60 (7) 977-984
    CrossrefPubMedGoogle Scholar
  • 7 Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis 2005; 9 (1) 37-53
    CrossrefPubMedGoogle Scholar
  • 8 Adachi M, Brenner DA. Clinical syndromes of alcoholic liver disease. Dig Dis 2005; 23 (3-4) 255-263
    CrossrefPubMedGoogle Scholar
  • 9 Altamirano J, Miquel R, Katoonizadeh A , et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 2014; 146 (5) 1231-9.e1 , 6
    CrossrefPubMedGoogle Scholar
  • 10 Tiniakos DG. Liver biopsy in alcoholic and non-alcoholic steatohepatitis patients. Gastroenterol Clin Biol 2009; 33 (10-11) 930-939
    CrossrefPubMedGoogle Scholar
  • 11 Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004; 127 (5) (Suppl. 01) S87-S96
    CrossrefPubMedGoogle Scholar
  • 12 Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003; 37 (3) 493-503
    CrossrefPubMedGoogle Scholar
  • 13 Altamirano J, Bataller R. Cigarette smoking and chronic liver diseases. Gut 2010; 59 (9) 1159-1162
    CrossrefPubMedGoogle Scholar
  • 14 Naveau S, Dobrin AS, Balian A , et al. Body fat distribution and risk factors for fibrosis in patients with alcoholic liver disease. Alcohol Clin Exp Res 2013; 37 (2) 332-338
    CrossrefPubMedGoogle Scholar
  • 15 Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005; 129 (6) 1928-1936
    CrossrefPubMedGoogle Scholar
  • 16 Dranoff JA, Feld JJ, Lavoie EG, Fausther M. How does coffee prevent liver fibrosis? Biological plausibility for recent epidemiological observations. Hepatology 2014; 60 (2) 464-467
    PubMedGoogle Scholar
  • 17 Goh GB, Chow WC, Wang R, Yuan JM, Koh WP. Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatology 2014; 60 (2) 661-669
    CrossrefPubMedGoogle Scholar
  • 18 Askgaard G, Grønbæk M, Kjær MS, Tjønneland A, Tolstrup JS. Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study. J Hepatol 2015;
    PubMedGoogle Scholar
  • 19 Corrao G, Bagnardi V, Zambon A, Torchio P. Meta-analysis of alcohol intake in relation to risk of liver cirrhosis. Alcohol Alcohol 1998; 33 (4) 381-392
    CrossrefPubMedGoogle Scholar
  • 20 Day CP. Who gets alcoholic liver disease: nature or nurture? (extended abstract). Acta Gastroenterol Belg 2003; 66 (4) 290-291 , discussion 292–293
    PubMedGoogle Scholar
  • 21 Stickel F, Osterreicher CH. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol 2006; 41 (3) 209-224
    CrossrefPubMedGoogle Scholar
  • 22 Hrubec Z, Omenn GS. Evidence of genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism and its biological end points by zygosity among male veterans. Alcohol Clin Exp Res 1981; 5 (2) 207-215
    CrossrefPubMedGoogle Scholar
  • 23 Druesne-Pecollo N, Tehard B, Mallet Y , et al. Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer. Lancet Oncol 2009; 10 (2) 173-180
    CrossrefPubMedGoogle Scholar
  • 24 Zintzaras E, Stefanidis I, Santos M, Vidal F. Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease?. Hepatology 2006; 43 (2) 352-361
    CrossrefPubMedGoogle Scholar
  • 25 Li D, Zhao H, Gelernter J. Strong protective effect of the aldehyde dehydrogenase gene (ALDH2) 504lys (*2) allele against alcoholism and alcohol-induced medical diseases in Asians. Hum Genet 2012; 131 (5) 725-737
    CrossrefPubMedGoogle Scholar
  • 26 Chen P, Schnabl B. Host-microbiome interactions in alcoholic liver disease. Gut Liver 2014; 8 (3) 237-241
    CrossrefPubMedGoogle Scholar
  • 27 Leclercq S, Matamoros S, Cani PD , et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci U S A 2014; 111 (42) E4485-E4493
    CrossrefPubMedGoogle Scholar
  • 28 Marcos M, Pastor I, González-Sarmiento R, Laso FJ. Common polymorphisms in interleukin genes (IL4, IL6, IL8 and IL12) are not associated with alcoholic liver disease or alcoholism in Spanish men. Cytokine 2009; 45 (3) 158-161
    CrossrefPubMedGoogle Scholar
  • 29 Wang Y, Hu Y, Chao C , et al. Role of IRAK-M in alcohol induced liver injury. PLoS ONE 2013; 8 (2) e57085
    CrossrefPubMedGoogle Scholar
  • 30 Roy N, Mukhopadhyay I, Das K , et al. Genetic variants of TNFα, IL10, IL1β, CTLA4 and TGFβ1 modulate the indices of alcohol-induced liver injury in East Indian population. Gene 2012; 509 (1) 178-188
    CrossrefPubMedGoogle Scholar
  • 31 Zeng T, Zhang CL, Han XY, Zhao S, Xie KQ. Association between CD14-159C>T polymorphisms and the risk for alcoholic liver disease: a meta-analysis. Eur J Gastroenterol Hepatol 2013; 25 (10) 1183-1189
    PubMedGoogle Scholar
  • 32 Nahon P, Sutton A, Pessayre D , et al. Genetic dimorphism in superoxide dismutase and susceptibility to alcoholic cirrhosis, hepatocellular carcinoma, and death. Clin Gastroenterol Hepatol 2005; 3 (3) 292-298
    CrossrefPubMedGoogle Scholar
  • 33 Marcos M, Pastor I, Chamorro AJ, Ciria-Abad S, González-Sarmiento R, Laso FJ. Meta-analysis: glutathione-S-transferase allelic variants are associated with alcoholic liver disease. Aliment Pharmacol Ther 2011; 34 (10) 1159-1172
    CrossrefPubMedGoogle Scholar
  • 34 Trépo E, Nahon P, Bontempi G , et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology 2014; 59 (6) 2170-2177
    CrossrefPubMedGoogle Scholar
  • 35 Friedrich K, Rupp C, Hov JR , et al. A frequent PNPLA3 variant is a sex specific disease modifier in PSC patients with bile duct stenosis. PLoS ONE 2013; 8 (3) e58734
    CrossrefPubMedGoogle Scholar
  • 36 Dongiovanni P, Donati B, Fares R , et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013; 19 (41) 6969-6978
    CrossrefPubMedGoogle Scholar
  • 37 Stickel F, Buch S, Lau K , et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in Caucasians. Hepatology 2011; 53 (1) 86-95
    CrossrefPubMedGoogle Scholar
  • 38 Lin CW, Lin CC, Mo LR , et al. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. J Hepatol 2013; 58 (4) 730-735
    CrossrefPubMedGoogle Scholar
  • 39 Innes HA, Hutchinson SJ, Barclay S , et al; Hepatitis C Clinical Database Monitoring Committee. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. Hepatology 2013; 57 (2) 451-460
    CrossrefPubMedGoogle Scholar
  • 40 Greenfield JR, Samaras K, Hayward CS, Chisholm DJ, Campbell LV. Beneficial postprandial effect of a small amount of alcohol on diabetes and cardiovascular risk factors: modification by insulin resistance. J Clin Endocrinol Metab 2005; 90 (2) 661-672
    CrossrefPubMedGoogle Scholar
  • 41 Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25 (1) 108-111
    CrossrefPubMedGoogle Scholar
  • 42 Bataller R, Rombouts K, Altamirano J, Marra F. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2011; 25 (2) 231-244
    CrossrefPubMedGoogle Scholar
  • 43 Wood MJ, Powell LW, Ramm GA. Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 2008; 111 (9) 4456-4462
    CrossrefPubMedGoogle Scholar
  • 44 Sorrentino P, Terracciano L, D'Angelo S , et al. Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis. J Gastroenterol 2010; 45 (10) 1053-1062
    CrossrefPubMedGoogle Scholar
  • 45 Bunchorntavakul C, Reddy KR. Acetaminophen-related hepatotoxicity. Clin Liver Dis 2013; 17 (4) 587-607 , viii
    CrossrefPubMedGoogle Scholar
  • 46 Lieber CS, DeCarli LM, Mak KM, Kim CI, Leo MA. Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated lecithin. Hepatology 1990; 12 (6) 1390-1398
    CrossrefPubMedGoogle Scholar
  • 47 Kisseleva T, Cong M, Paik Y , et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A 2012; 109 (24) 9448-9453
    CrossrefPubMedGoogle Scholar
  • 48 Lazaro R, Wu R, Lee S , et al. Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. Hepatology 2015; 61 (1) 129-140
    CrossrefPubMedGoogle Scholar
  • 49 Jeong WI, Park O, Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology 2008; 134 (1) 248-258
    CrossrefPubMedGoogle Scholar
  • 50 Chiang DJ, Roychowdhury S, Bush K , et al. Adenosine 2A receptor antagonist prevented and reversed liver fibrosis in a mouse model of ethanol-exacerbated liver fibrosis. PLoS ONE 2013; 8 (7) e69114
    CrossrefPubMedGoogle Scholar
  • 51 Karaca G, Xie G, Moylan C , et al. Role of Fn14 in acute alcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 2015; 308 (4) G325-G334
    CrossrefPubMedGoogle Scholar
  • 52 Li JP, Gao Y, Chu SF , et al. Nrf2 pathway activation contributes to anti-fibrosis effects of ginsenoside Rg1 in a rat model of alcohol- and CCl4-induced hepatic fibrosis. Acta Pharmacol Sin 2014; 35 (8) 1031-1044
    CrossrefPubMedGoogle Scholar
  • 53 Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-456
    CrossrefPubMedGoogle Scholar
  • 54 Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115 (2) 209-218
    CrossrefPubMedGoogle Scholar
  • 55 Chedid A, Arain S, Snyder A, Mathurin P, Capron F, Naveau S. The immunology of fibrogenesis in alcoholic liver disease. Arch Pathol Lab Med 2004; 128 (11) 1230-1238
    PubMedGoogle Scholar
  • 56 Sakhuja P. Pathology of alcoholic liver disease, can it be differentiated from nonalcoholic steatohepatitis?. World J Gastroenterol 2014; 20 (44) 16474-16479
    CrossrefPubMedGoogle Scholar
  • 57 Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88 (1) 125-172
    CrossrefPubMedGoogle Scholar
  • 58 Mederacke I, Hsu CC, Troeger JS , et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 2013; 4: 2823
    PubMedGoogle Scholar
  • 59 Seki E, Schwabe RF. Hepatic inflammation and fibrosis: Functional links and key pathways. Hepatology 2015; 61 (3) 1066-1079
    CrossrefPubMedGoogle Scholar
  • 60 Kwon HJ, Won YS, Park O , et al. Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice. Hepatology 2014; 60 (1) 146-157
    CrossrefPubMedGoogle Scholar
  • 61 Setshedi M, Wands JR, Monte SM. Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev 2010; 3 (3) 178-185
    CrossrefPubMedGoogle Scholar
  • 62 Mello T, Ceni E, Surrenti C, Galli A. Alcohol induced hepatic fibrosis: role of acetaldehyde. Mol Aspects Med 2008; 29 (1-2) 17-21
    CrossrefPubMedGoogle Scholar
  • 63 Tilg H, Gao B. Dietary saturated lipids in alcoholic liver disease: new microbiota-targeting bullets?. Gastroenterology 2015; 148 (1) 16-19
    CrossrefPubMedGoogle Scholar
  • 64 Chen P, Torralba M, Tan J , et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 2015; 148 (1) 203-214.e16
    CrossrefPubMedGoogle Scholar
  • 65 Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006; 130 (2) 435-452
    CrossrefPubMedGoogle Scholar
  • 66 Melhem A, Muhanna N, Bishara A , et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 2006; 45 (1) 60-71
    CrossrefPubMedGoogle Scholar
  • 67 Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol 2011; 4 (6) 391-417
    CrossrefPubMedGoogle Scholar
  • 68 J Torok N, Dranoff JA, Schuppan D, Friedman SL. Strategies and endpoints of antifibrotic drug trials: summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology 2015; [In press]
    PubMedGoogle Scholar
  • 69 Kong X, Feng D, Wang H , et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 2012; 56 (3) 1150-1159
    CrossrefPubMedGoogle Scholar
  • 70 Feng D, Kong X, Weng H , et al. Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology 2012; 143 (1) 188-98.e7
    CrossrefPubMedGoogle Scholar
  • 71 Ki SH, Park O, Zheng M , et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 2010; 52 (4) 1291-1300
    CrossrefPubMedGoogle Scholar
  • 72 European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57 (2) 399-420
    CrossrefPubMedGoogle Scholar
  • 73 Hock B, Schwarz M, Domke I , et al. Validity of carbohydrate-deficient transferrin (CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction 2005; 100 (10) 1477-1486
    CrossrefPubMedGoogle Scholar
  • 74 Alatalo P, Koivisto H, Puukka K , et al. Biomarkers of liver status in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcohol 2009; 44 (2) 199-203
    CrossrefPubMedGoogle Scholar
  • 75 Torruellas C, French SW, Medici V. Diagnosis of alcoholic liver disease. World J Gastroenterol 2014; 20 (33) 11684-11699
    CrossrefPubMedGoogle Scholar
  • 76 MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis 1986; 6 (3) 221-232
    Article in Thieme ConnectPubMedGoogle Scholar
  • 77 Singh DK, Rastogi A, Sakhuja P, Gondal R, Sarin SK. Comparison of clinical, biochemical and histological features of alcoholic steatohepatitis and non-alcoholic steatohepatitis in Asian Indian patients. Indian J Pathol Microbiol 2010; 53 (3) 408-413
    CrossrefPubMedGoogle Scholar
  • 78 Mueller S, Seitz HK, Rausch V. Non-invasive diagnosis of alcoholic liver disease. World J Gastroenterol 2014; 20 (40) 14626-14641
    CrossrefPubMedGoogle Scholar
  • 79 Chrostek L, Panasiuk A. Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol 2014; 20 (25) 8018-8023
    CrossrefPubMedGoogle Scholar
  • 80 Mueller S, Millonig G, Sarovska L , et al. Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol 2010; 16 (8) 966-972
    CrossrefPubMedGoogle Scholar
  • 81 Gelsi E, Dainese R, Truchi R , et al. Effect of detoxification on liver stiffness assessed by Fibroscan® in alcoholic patients. Alcohol Clin Exp Res 2011; 35 (3) 566-570
    CrossrefPubMedGoogle Scholar
  • 82 Penny SM. Alcoholic liver disease. Radiol Technol 2013; 84 (6) 577-592 , quiz 593–595
    PubMedGoogle Scholar
  • 83 d'Assignies G, Fontés G, Kauffmann C , et al. Early detection of liver steatosis by magnetic resonance imaging in rats infused with glucose and intralipid solutions and correlation to insulin levels. Metabolism 2013; 62 (12) 1850-1857
    CrossrefPubMedGoogle Scholar
  • 84 Mookerjee RP, Lackner C, Stauber R , et al. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J Hepatol 2011; 55 (5) 1103-1111
    CrossrefPubMedGoogle Scholar
  • 85 Murray KF, Carithers Jr RL ; AASLD. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41 (6) 1407-1432
    CrossrefPubMedGoogle Scholar
  • 86 O'Shea RS, Dasarathy S, McCullough AJ ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 2010; 51 (1) 307-328
    CrossrefPubMedGoogle Scholar
  • 87 Rincon D, Lo Iacono O, Ripoll C , et al. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis. Aliment Pharmacol Ther 2007; 25 (7) 841-848
    CrossrefPubMedGoogle Scholar
  • 88 Williams MJ, Clouston AD, Forbes SJ. Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. Gastroenterology 2014; 146 (2) 349-356
    CrossrefPubMedGoogle Scholar
  • 89 Colmenero J, Bataller R, Sancho-Bru P , et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology 2007; 132 (2) 687-697
    CrossrefPubMedGoogle Scholar
  • 90 Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S ; Veterans Affairs Cooperative Study 391 Group. II. Veterans Affairs Cooperative Study of Polyenylphosphatidylcholine in Alcoholic Liver Disease. Alcohol Clin Exp Res 2003; 27 (11) 1765-1772
    CrossrefPubMedGoogle Scholar
  • 91 Verrill C, Markham H, Templeton A, Carr NJ, Sheron N. Alcohol-related cirrhosis—early abstinence is a key factor in prognosis, even in the most severe cases. Addiction 2009; 104 (5) 768-774
    CrossrefPubMedGoogle Scholar
  • 92 Vuittonet CL, Halse M, Leggio L , et al. Pharmacotherapy for alcoholic patients with alcoholic liver disease. Am J Health Syst Pharm 2014; 71 (15) 1265-1276
    CrossrefPubMedGoogle Scholar
  • 93 Masson S, Emmerson I, Henderson E , et al. Clinical but not histological factors predict long-term prognosis in patients with histologically advanced non-decompensated alcoholic liver disease. Liver Int 2014; 34 (2) 235-242
    CrossrefPubMedGoogle Scholar
  • 94 Takahashi H, Shigefuku R, Maeyama S , et al. Cirrhosis improvement to alcoholic liver fibrosis after passive abstinence. BMJ Case Rep 2014;
    PubMedGoogle Scholar
  • 95 Thompson KJ, McKillop IH, Schrum LW. Targeting collagen expression in alcoholic liver disease. World J Gastroenterol 2011; 17 (20) 2473-2481
    CrossrefPubMedGoogle Scholar
  • 96 Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev 2012; 92 (4) 1515-1542
    CrossrefPubMedGoogle Scholar
  • 97 Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2006; (2) CD002235
    PubMedGoogle Scholar
  • 98 Kim MY, Cho MY, Baik SK , et al. Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - a randomized open-label controlled study. Liver Int 2012; 32 (6) 977-987
    CrossrefPubMedGoogle Scholar
  • 99 Bertola A, Park O, Gao B. Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: a critical role for E-selectin. Hepatology 2013; 58 (5) 1814-1823
    CrossrefPubMedGoogle Scholar
  • 100 National Institute on Alcohol Abuse and Alcoholism. Translational Research in Alcoholic Hepatitis. Available at: http://grants.nih.gov/grants/guide/rfa-files/RFA-AA-12-007.html . Accessed March 20, 2015
    PubMedGoogle Scholar